Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Let’s Not Support the Insanity of Support.com Stock

By David Moadel, InvestorPlace Contributor
SPRT stock may have gone up too far, too fast as frenzied retail traders bet on a smooth, cryptocurrency-focused business combination.

Don’t Try to Catch the Falling Knife With Marin Software

By Thomas Niel, InvestorPlace Contributor
The circumstances that shot MRIN stock to the moon a month ago aren't likely to repeat anytime soon. Expect share prices to fall even more.

Investors Should Avoid SOS Stock Until It Drops to Its Cash Per Share

By Mark R. Hake, CFA
Investors should avoid SOS stock until it drops to its cash per share. Wait until SOS stock falls to between 56 cents and 70 cents per share, or its cash per share, before buying in.

With the Endgame in Sight, Investors Should Steer Clear of GameStop Stock

By Joel Baglole, InvestorPlace Contributor
Has the Reddit crowd finally moved on from GameStop? It certainly looks that way with GME stock down 14% over the past week and down 26% in the last month. At $147 a share, the company's share price has fallen 70% from its all-time high of $483.00 reached in January of this year when it was the favorite meme stock of the retail traders who frequent the WallStreetBets sub-Reddit site.

The Bear Case for Atossa Therapeutics Makes More Sense at This Time

By Muslim Farooque, InvestorPlace Contributor
Investors have become wary of the risks surrounding Atossa's pipeline. That caution will continue pulling down ATOS stock

Carnival Stock Could Be Heading for More Choppy Waters

By Tezcan Gecgil, InvestorPlace Contributor
Carnival is unable to gain momentum during the peak summer season

Virgin Galactic Is Vulnerable To Inevitable Regulatory Intervention

By Josh Enomoto, InvestorPlace Contributor
Thanks to the volatility of SPCE stock, day traders can make serious profits over a short frame but this condition might not last.

Sundial Growers’ Only Chance Lies with Unlikely U.S. Legalization

By Stavros Georgiadis, CFA, InvestorPlace Contributor
SNDL stock is a speculative bet on the cannabis industry. Its financial performance and valuation do not support it as a buy at all.

ViacomCBS Is Losing Multiple Battles in the Streaming Wars

By Larry Ramer, InvestorPlace Contributor
ViacomCBS is behind in the streaming wars, and its cable TV and movie businesses are becoming obsolete. This is a bad time to own VIAC stock.

Nio Stock Looks Vulnerable Ahead of a Critical Earnings Report

By Josh Enomoto, InvestorPlace Contributor
While NIO stock bounced back from its Q1 disappointment, the upcoming Q2 report will be crucial in setting the framework.

UBER Stock Looks Desperate Going Into Earnings, so Stay Clear for Now

By Alex Sirois, InvestorPlace Contributor
UBER stock could be in big trouble or on the cusp of great success but it's best to steer clear for the time being.

Bionano’s Technology Is Interesting, But Its Earnings Are Uninspiring

By Ian Bezek, InvestorPlace Contributor
Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals.

Throw in The Towel, Ocugen Stock is Not Coming Back

By Thomas Niel, InvestorPlace Contributor
Barring the slim chance it gets EUA in Canada, which admittedly could result in an outsized move higher? Expect OCGN stock to continue trending lower, eventually falling back to around 70 cents per share.

7 F-Rated Stocks to Avoid for the Rest of 2021

By Louis Navellier and the InvestorPlace Research Staff
In a churning market like this, you want to steer clear of stocks that are floundering. Here are sevens stocks to avoid today.

There’s Little That’s Attractive About Once-Hot Zomedica Stock… for Now

By Ian Cooper, InvestorPlace Contributor
Zomedica has become a slow-motion train wreck. ZOM stock investors should look for alternatives to the animal diagnostics firm.

Marin Software Stock Has Very Little To Offer as Its Meme Status Fades Away

By Larry Ramer, InvestorPlace Contributor
Marin's financial results are unimpressive and meme stocks are weakening, making MRIN stock unappealing at this time.

Covid-19 Vaccine Dose Delay Spells Even More Trouble for Novavax Stock

By David Moadel, InvestorPlace Contributor
Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress.

Investors Should Avoid High-Risk Atossa Therapeutics

By Larry Ramer, InvestorPlace Contributor
Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point.

Clover Stock Is Really Unlikely To Get Squeezed Again

By Thomas Niel, InvestorPlace Contributor
There's a reason why CLOV stock has been shorted heavily. With trading trends no longer your friend, there's little reason to dive in today.
Load More Articles